PYX Resources: Achieving volume and diversification milestones. Watch the video here.
Apologies my phone played up before I could complete.
Includes Professor Wilkinson and is on the Synairgen's trial.
https://ccf-nihr.zoom.us/webinar/register/WN_KZLwXfmUQaS3Cu0-UU48Zw
https://twitter.com/ManchesterCRF/status/1329395923282169856?s=20
Joey Diamond, the Pfizer vaccine would be a good guess. I missed the point that it was categorised as prevention rather than treatment which SNG is perhaps more likely to be positioned as, plus being Chemical as Pjmh pointed out is also likely to rule us out.
Bumping up an old thread as latest CHMP meeting highlights from earlier this week and annexure now released.
https://www.ema.europa.eu/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-9-12-november-2020_en.pdf
List now further shortened to :
Prevention of COVID-19 disease x 4
Treatment of COVID-19 disease x 2
For October it was:
Prevention of COVID-19 disease x 5
Treatment of COVID-19 disease x 3
Treatment and prevention of COVID-19 disease x 1
This month there is a new candidate under Chemical substance now added for discussion under Protocol Assistance , with ticks under Clinical and more interesingly "Significant Benefit" which none of the other candidates have.
Wonder what this one could be, but I could only think of one!
EU laws on medicine will continue to apply until the end of the transitional period as stated here.
https://www.ema.europa.eu/en/about-us/brexit-united-kingdoms-withdrawal-european-union
The CAT committee's meeting concludes today and includes discussion on PRIME medicines including commercially sensitive medicines as set out in the agenda.
https://www.ema.europa.eu/documents/agenda/agenda-cat-agenda-4-6-november-2020-meeting_en.pdf
The next CHMP meeting takes place next week between 9th and 12th November.
Now whether SNG will be discussed and if it has even put in an application for PRIME authorisation is all guess work, but the only part certain is that it has been discussed by the EMA as it is present on the list of potential discussed treatments, so is very much on EMA's radar.
https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19
Note the company name has been spelt as Synargein.
Fingers crossed that we do hear some positive update in the next few days.
Looking at the trades today some massive buys in there, so some accumulations going on there. Sells look to be small trades, so PIs selling on the back of their 10 - 15% gains.
If the SP manages to close above 15p today, then hopefully this becomes the support for the next leg up.
- phase 2/3 trial
- not just looking at hospital settings but community, so am guessing care homes as well
- considering a wide range of Respiratory diseases, so not just limited to Covid. Therefore doesn't really require positive covid test
- will be carried out at no cost to the Company, so no need for further funds or dilution. But of course any positive conclusion will massively benefit the company, so it is win win.
- recruitment to begin immediately
Brilliant news on all front. Still can't believe how much under the radar the company is, and how it is still a 20m mcap company.
Brilliant RNS. This deal kills many birds at the same time. Access to immediate cash plus with Nasdaq listing the mcap will shoot up to more realistic valuation vs Seres, plus interest will shoot up for access to new capital whenever needed.
Pmjh, could France be one of them?
Interesting tweet from Mary Aurélien who is talking about inhaled interferon beta trial possibly in CHU Amiens today.
https://twitter.com/MARYau_MCU_PH/status/1318119934296248320?s=20
I can't however access this link as its subscription only.
https://premium.courrier-picard.fr/id134100/article/2020-10-17/covid-19-de-largent-pour-un-essai-clinique-sur-linterferon-au-chu
This is from Synairgen's website. Reading through it suggests SNG001 can be positioned for both prevention and treatment.
"Synairgen is developing a formulation of IFN-beta, called SNG001, for direct delivery to the lungs via nebulisation, to treat and/or prevent LRT illness caused by respiratory viruses."
https://www.synairgen.com/covid-19/
There is another document related to the meeting which has a few lines related to Covid treatments. However, I am unsure if this has any significance.
https://www.ema.europa.eu/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-12-15-october-2020_en.pdf
Meeting highlights just in. Can't find any mention of Covid drugs.
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020
There is actually a seminar presentation by the IHU Méditerranée Infection Foundation based in Marseille France released 2 days back discussing about Interferon Beta and its effectiveness for Covid 19.
https://youtu.be/W9Tl7i_EbGU
Unfortunately the presentation is in French which I don't understand a word of, but they definitely mention SNG at about 27 minutes.
The video has already raked in 28k views in 2 days, so looks like Interferon Beta is definitely a hot topic in France with the fight against Covid 19 atleast amongst the medical community who I assume would be the main viewers - the Institute has 200k+ subscribers.
Not sure if this has any significance to the French ATU topic which has also been under discussion for SNG.
Good show of confidence by the Directors buying at this level from the positive RNS release this evening. Hopefully this will help in stopping the slow drift downwards and will give investors a good base to start buying again.